Experience with tenofovir disoproxil fumarate for antiretroviral therapy

Abstract

Background and rationale/objective: Tenofovir disoproxil fumarate was approved in the US in 2001 and a few months later by the European Medicines Evaluation Agency for use in the EU, initially for treatment-experienced HIV patients with early virological failure. The following year the HIV indication was expanded to include antiretroviral treatment naïve adults over 18 years of age. Results and conclusions: Ongoing clinical trials of tenofovir disoproxil fumarate's safety and efficacy have confirmed its position as a long-term, safe, effective and convenient backbone component in combination antiretroviral therapy for HIV-infected patients. With its favourable resistance profile, it is also an option for treatment-experienced patients. This article describes the efficacy and safety of tenofovir disoproxil fumarate from ongoing and recent clinical trials, and key aspects of its broad, clinical experience since its introduction.

Keywords::

• efficacy
• hepatitis B
• renal safety
• safety
• switch studies
• tenofovir
• Viread

Acknowledgement and declaration of interest

The author acknowledges Gilead Sciences for assistance in preparing and editing this manuscript.

Notes